ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ZIOPHARM (ZIOP) Looking to Partner for Cancer Drug Development
February 12, 2013 1:45 PM ESTZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) CEO Jonathan Lewis said the pharma is in talks for a partnership over its cancer drug. He also said the company's drug for soft-tissue sarcoma is in late-stage testing.
Comments were made during an interview with Bloomberg.... More
